These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 34465124)

  • 1. Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction.
    Ozaki AF; Krumholz HM; Mody FV; Tran TT; Le QT; Yokota M; Jackevicius CA
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007665. PubMed ID: 34465124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Trends in the Use of Sacubitril/Valsartan.
    Ozaki AF; Krumholz HM; Mody FV; Jackevicius CA
    J Card Fail; 2021 Aug; 27(8):839-847. PubMed ID: 34364661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use and Out-of-Pocket Cost of Sacubitril-Valsartan in Patients With Heart Failure.
    Shore S; Basu T; Kamdar N; Brady P; Birati E; Hummel SL; Chopra V; Nallamothu BK
    J Am Heart Assoc; 2022 Sep; 11(17):e023950. PubMed ID: 36000415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.
    Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM
    Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Carnicelli AP; Li Z; Greiner MA; Lippmann SJ; Greene SJ; Mentz RJ; Hardy NC; Blumer V; Shen X; Yancy CW; Peterson PN; Allen LA; Fonarow GC; O'Brien EC
    JACC Heart Fail; 2021 Dec; 9(12):876-886. PubMed ID: 34509408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.
    Sumarsono A; Vaduganathan M; Ajufo E; Navar AM; Fonarow GC; Das SR; Pandey A
    JAMA Cardiol; 2020 Mar; 5(3):336-339. PubMed ID: 31738371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
    Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
    Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; Abbas CA; Desai AS;
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.
    Sandhu AT; Ollendorf DA; Chapman RH; Pearson SD; Heidenreich PA
    Ann Intern Med; 2016 Nov; 165(10):681-689. PubMed ID: 27571284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction.
    Barman HA; Tanyolaç S; Dogan O; Bal E; Atıcı A; Özyıldırım S; Yiğit Z
    Clin Drug Investig; 2022 Jun; 42(6):533-540. PubMed ID: 35635714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries.
    Bhatt AS; Vaduganathan M; Solomon SD; Schneeweiss S; Lauffenburger JC; Desai RJ
    Eur J Heart Fail; 2022 Sep; 24(9):1506-1515. PubMed ID: 35689603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction.
    Dereli S; Kılınçel O; Çerik İB; Kaya A
    Acta Cardiol; 2020 Dec; 75(8):774-782. PubMed ID: 32186467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.